KẾT QUẢ ĐIỀU TRỊ RIBOCICLIB KẾT HỢP FULVESTRANT TRÊN BỆNH NHÂN UNG THƯ VÚ GIAI ĐOẠN TÁI PHÁT, DI CĂN CÓ THỤ THỂ NỘI TIẾT DƯƠNG TÍNH, HER2 ÂM TÍNH

Abstract

Objectives: To evaluate the efficacy and adverse effects of the Ribociclib combined with Fulvestrant regimen in patients with recurrent or metastatic breast cancer. Methods: A retrospective and prospective descriptive study. From January 2020 to July 2024, the study enrolled 40 patients with hormone receptor-positive, HER2-negative recurrent and metastatic breast cancer at K Hospital. Result: The mean age was 56.0 years (range: 36–80 years). Common sites of metastasis included bone (60.0%), lung (42.5%), and liver (35.0%). The objective response rate was 45.0%, and clinical benefit rate was 57.5%, including 2.5% of patients achieving complete response, 42.5% with partial response, and 12.5% with stable disease. Median progression-free survival was 15.9 months. Patients generally tolerated the treatment well; 47.5% required at least one dose reduction, and 5% discontinued treatment due to adverse effects. Conclusion: Treatment with Ribociclib in combination with Fulvestrant for recurrent and metastatic hormone receptor-positive, HER2-negative breast cancer is both effective and safe. Therefore, this regimen should be widely adopted in clinical practice.